Control of cytomegalovirus retinitis after combination antiretroviral therapy.
OBJECTIVE
To report on AIDS patients having combination antiretroviral therapy whose cytomegalovirus (CMV) retinitis remained inactive after discontinuation of anti-CMV maintenance therapy.


METHODS
We describe the course of CMV-retinitis in 3 patients with AIDS after initiation of combination antiretroviral therapy.


RESULTS
After cessation of anti-CMV therapy no relapse of CMV-retinitis has been observed for up to 18 months. Two of the patients developed new CMV-retinitis in the first months after initiation of combination therapy, nevertheless after further improvement of immunological parameters retinitis remained stable without anti-CMV therapy.


CONCLUSIONS
The sustained immunological effects of combination therapy are possibly sufficient enough to provide protection against CMV-retinitis.
Ruhswurm
I
I
Department of Ophthalmology, University of Vienna, Medical School, Austria.
Ries
E
E
Krepler
K
K
Derbolav
A
A
Rieger
A
A
Armbruster
C
C
Wedrich
A
A
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use*; D006678:HIV / Q000235:genetics; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D019258:Saquinavir / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D012367:RNA, Viral; D019469:Indinavir; D019258:Saquinavir; D015774:Ganciclovir